OSE Immunotherapeutics is a biotechnology company that focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. It offers Memopi technology to activate the immune system based on a patented combination of neo-epitopes; Tedopi, a T specific immunotherapy that is in Phase III clinical stage for the treatment of lung cancer in the United States, Israel, and Europe, as well as in Phase II clinical trials to treat ovarian, colon, or breast cancers.